Attached files
| file | filename |
|---|---|
| EX-99.1 - China Shenghuo Pharmaceutical Holdings Inc | v197515_ex99-1.htm |
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
report (Date of earliest event reported): September 22,
2010
CHINA
SHENGHUO PHARMACEUTICAL HOLDINGS, INC.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction
of
Incorporation)
|
001-33537
|
20-2903562
|
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
No.
2, Jing You Road
|
|
|
Kunming
National Economy &
|
|
|
Technology
Developing District
|
|
|
People’s
Republic of China 650217
|
N/A
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
0086-871-728-2628
( Registrant’s Telephone Number,
Including Area Code)
N/A
(Former
Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General
Instruction A.2. below):
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
On
September 22, 2010, China Shenghuo Pharmaceutical Holdings, Inc. (the “Company”)
received a deficiency letter (the “Deficiency Letter”) from the NYSE Amex LLC
(“AMEX”) stating that, as a result of the Company having stockholders’ equity of
less than $2,000,000, losses from continuing operations and net losses in two
out of its three most recent fiscal years, the Company is no longer in
compliance with Section 1003(a)(i) of the AMEX’s Company Guide (the “Company
Guide”). The Deficiency Letter states that, in order to maintain its
AMEX listing, the Company must submit a plan of compliance (the “Plan”), by
October 22, 2010, advising the AMEX of actions the Company has taken, or will
take, to regain compliance with Section 1003(a)(i) of the Company Guide by no
later than March 22, 2012. The Company has contacted AMEX to confirm
the Company’s receipt of the Deficiency Letter and its intention to submit the
Plan.
Pursuant
to the Deficiency Letter, if the AMEX determines that the Company has made a
reasonable demonstration in the Plan of an ability to regain compliance with the
continued listing standards by March 22, 2012, the AMEX will accept the
Plan. If the AMEX does not accept the Plan, or the Company does not
make adequate progress and complete the actions outlined in the Plan by March
22, 2012, the AMEX will initiate delisting proceedings against the
Company.
The
Company’s unaudited net loss attributable to stockholders for the six months
ended June 30, 2010, was narrowed to $28,837 as compared to an unaudited net
loss attributable to stockholders of $6.7 million for the six months ended June
30, 2009. The Company expects to be profitable for the nine months
ending September 30, 2010 and for the full fiscal year ending December 31,
2010. The Plan that the Company will present to the AMEX will show
that the Company projects that within the 18-month plan period its stockholders’
equity will increase to the $2 million level as a result of its internally
generated return to profitability. Should the Company issue equity,
whether in a private or public offering during that period, it would accelerate
meeting this target. However, there can be no assurance that the AMEX
will find the Plan to be submitted to be acceptable or, even if accepted, that
the Company will in fact generate sufficient net profit to achieve the requisite
stockholders’ equity threshold. Therefore, the Company can provide no
assurances that it will regain compliance with the AMEX’s continued listing
standards, and its failure to do so could result in the delisting of the
Company’s common stock from the AMEX. Until the Company achieves
compliance with the AMEX’s requirements, the Company’s stock trading symbol will
be appended with the “.BC” extension.
On
September 27, 2010, the Company issued a press release announcing receipt of the
Deficiency Letter from the AMEX. A copy of that press release is
attached to this Current Report on Form 8-K as Exhibit 99.1, and the information
therein is incorporated herein by reference.
|
(d)
|
Exhibits.
|
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Press
Release, dated September 27, 2010
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
CHINA
SHENGHUO
PHARMACEUTICAL
HOLDINGS, INC.
|
|||
|
Date:
September 27, 2010
|
|||
|
By:
|
/s/
Gui Hua Lan
|
||
|
Name:
Gui Hua Lan
|
|||
|
Title:
Chief Executive Officer
|
|||
EXHIBIT
INDEX
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Press
Release, dated September 27, 2010
|